An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent

W Yan, C Xiangyu, L Ya, W Yu, X Feng - Investigational New Drugs, 2019 - Springer
Liver cancer is a kind of high mortality cancer due to the difficulty of early diagnosis. It is
necessary to develop the anticancer agents to treat liver cancer. Here, a novel chalcone …

[HTML][HTML] Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study

S Xynogalos, D Simeonidis, G Papageorgiou… - Supportive Care in …, 2022 - Springer
Background Patients with active cancer have a 4–sevenfold increased risk for venous
thromboembolism (VTE) especially during systematic anticancer treatment. Simultaneously …

Metastatic bladder cancer: second-line treatment and recommendations of the genitourinary tumor division of the Galician Oncologic Society (SOG-GU)

J García, L Santomé, U Anido… - Current oncology …, 2016 - Springer
Once metastatic bladder cancer has progressed to first-line treatment, the number of
therapeutic options is scarce. Among chemotherapeutic agents showing activity in phase II …

Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials

A Schmitt, L Nguyen, G Zorza, P Ferré… - British journal of …, 2018 - Wiley Online Library
Aims Vinflunine is a novel tubulin‐targeted inhibitor indicated as a single agent for the
treatment of bladder cancers after failure of prior platinum‐based therapy. Its …

Vinflunine for the treatment of non-small cell lung cancer

C Genova, A Alama, S Coco, E Rijavec… - Expert Opinion on …, 2016 - Taylor & Francis
Introduction: Vinflunine belongs to the class of vinca alkaloids and acts by disrupting the
microtubule dynamics during cell cycle; this agent is currently available for previously …